V66

V66 is a humanized, cell-penetrating, nucleic acid-binding monoclonal antibody derived from the lupus-derived autoantibody 3E10 (specifically the 3E10-D31N variant). Developed by Yale University and licensed to Gennao Bio, V66 targets extracellular DNA (exDNA) in the tumor microenvironment and enters cells via the Equilibrative Nucleoside Transporter 2 (ENT2), which is overexpressed in various cancers. Once inside the cell, V66 localizes to the nucleus and binds to the DNA repair protein RAD51, inhibiting homology-directed repair and inducing synthetic lethality in DNA damage response (DDR)-deficient cells, such as BRCA2-deficient tumors. V66 is also utilized as a delivery platform for nucleic acid payloads (such as mRNA, siRNA, and ASOs) and has been engineered into antibody-drug conjugates (ADCs) like V66-exatecan for targeted cancer therapy.

Other names

humanized 3E10-D31Nhumanized3E10-D31Nhumanized-3E10-D31Nhumanized 3E10-D31N monoclonal antibodyhumanized3E10-D31N monoclonal antibodyhumanized-3E10-D31N monoclonal antibody